ArticleEFSA journal. European Food Safety Authority2025
Assessment of genetically modified maize DP202216 × NK603 × DAS-40278-9 (application GMFF-2022-6232).
Article in EFSA journal. European Food Safety Authority, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Considerations on the risk assessment of genetically modified plants containing transformation events stacked by conventional crossing.EFSA journal. European Food Safety Authority · 2026Article
- Assessment of genetically modified maize DP202216 × NK603 × DAS-40278-9 (application GMFF-2022-6232).EFSA journal. European Food Safety Authority · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetically modified maize DP202216 × NK603 × DAS 40278-9 was developed by crossing to combine three single events: DP202216, NK603 and DAS-40278-9. The three-event stack maize expresses PAT, CP4 EPSPS, CP4 EPSPS L124P, AAD-1 and the maize endogenous protein with altered expression (EPAE) ZMM28 to confer herbicide tolerance and to provide the potential for yield enhancement (PYE) under field conditions. The GMO Panel previously assessed the three single maize events and one of the sub-combinations and did not identify safety concerns. No new data on the single maize events or the assessed sub-combination were identified that could lead to modification of the original conclusions on their safety. The molecular characterisation, comparative analysis (agronomic, phenotypic and compositional characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicate that the combination of the single maize events and of the newly expressed proteins and the EPAE in the three-event stack maize does not give rise to food and feed safety or nutritional concerns. The GMO Panel concludes that three-event stack maize, as described in this application, is as safe as the non-GM comparator and non-GM reference varieties tested and no post-market monitoring of food/feed is considered necessary. In the case of the release of processed maize DP202216 × NK603 × DAS 40278-9 or accidental spillage of viable GM maize grains, into the environment, this would not raise environmental safety concerns. The GMO Panel assessed the likelihood of interactions among the single events in two of the maize sub-combinations not previously assessed and concludes that these are expected to be as safe as the single events, the previously assessed sub-combination and the three-event stack maize. The post-market environmental monitoring plan and reporting intervals are in line with the intended uses of maize DP202216 × NK603 × DAS 40278-9. The GMO Panel concludes that this three-event stack maize and its sub-combinations are as safe as its non-GM comparator and the tested non-GM reference varieties with respect to potential effects on human and animal health and the environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.